People live on average a little over two years after an mCRPC diagnosis. Find statistics here and learn how treatment ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

A McGill University-led research collaboration has achieved a breakthrough in understanding how cancer spreads. A clinical ...

A new class of molecules capable of killing the cancer cells that are refractory to standard treatments and responsible for recurrence has just been developed. This crucial advance in the fight ...

Researchers from the Endocrine Tumors group at the Germans Trias i Pujol Research Institute (IGTP), in collaboration with ...

Cells have a mailing system of sorts. They can release tiny molecular balls, called extracellular vesicles (EVs), that ...

Adding penpulimab to chemotherapy can improve progression-free survival for patients with recurrent or metastatic nasopharyngeal carcinoma, data suggest.

Bria-IMT plus checkpoint inhibitor therapy improved median overall survival in HR-positive and triple-negative metastatic breast cancer patients compared to Trodelvy. The phase 2 study showed 17.3 ...

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising results from a novel BMS androgen receptor antagonist and degrader in ...